Clinical Trials Logo

Clinical Trial Summary

The investigators assessed non-organ-specific antibodies before and 24 weeks after the end of therapy with direct-acting antivirals, in order to better clarify the clinical relevance of these antibodies in terms of treatment response and prognostic value. To achieve this goal patients with hepatitis C virus related advanced liver disease, with detectable circulating autoantibodies on at least two determinations before treatment, were enrolled.


Clinical Trial Description

About 40-70% of hepatitis C virus patients develop at least an autoimmune extra-hepatic disorder presumably due to the interaction between hepatitis C virus E2 envelope protein and B lymphocyte Cluster of Differentiation-81 receptor. In addition, the same interaction is responsible for the production of different serum non-organ-specific antibodies. The clinical significance of the latter phenomenon has not been fully understood except for the presence of liver kidney microsome-1 antibody, which is linked to a molecular mimicry between the cytochrome enzyme CYP2D6, primarily expressed in the liver, and hepatitis C virus proteins in genetically predisposed subjects. Actually, no data are available about the prevalence and clinical significance of serum non-organ-specific antibodies in hepatitis C virus patients treated with second generation direct-acting antivirals. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03566966
Study type Observational [Patient Registry]
Source University of Bari
Contact
Status Completed
Phase
Start date July 1, 2015
Completion date March 31, 2017

See also
  Status Clinical Trial Phase
Not yet recruiting NCT04470271 - Re-linkage to Care of Patients With Hepatitis C
Completed NCT03537196 - DRug Use & Infections in ViEtnam - Hepatitis C (DRIVE-C) Phase 4
Recruiting NCT05751889 - Serious Game Interventions to Reduce Viral Hepatitis C Among PLWH-MSM N/A
Completed NCT04047680 - eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs
Not yet recruiting NCT04690972 - "Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases".
Active, not recruiting NCT01953458 - Therapeutic Option for Hepatitis B and C: a French Cohort
Completed NCT02125500 - Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection Phase 2
Withdrawn NCT01766115 - Hepatitis C Virus Post-Exposure Prophylaxis for Health Care Workers Phase 4